Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guadecitabine and carboplatin in platinum-resistant ovarian cancer
NCT01696032Phase 2Completed
- Sponsor
- Astex Pharmaceuticals
- Start
- Sep 2012
- Primary completion
- Aug 2016
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 3
01
Overview
A Phase 2 trial of guadecitabine in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Astex Pharmaceuticals. Started Sep 2012; status: completed.
02
Drugs
guadecitabine
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01696032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01696032.